WO2016154047A3 - Monoclonal antigen-binding proteins to intracellular oncogene products - Google Patents
Monoclonal antigen-binding proteins to intracellular oncogene products Download PDFInfo
- Publication number
- WO2016154047A3 WO2016154047A3 PCT/US2016/023247 US2016023247W WO2016154047A3 WO 2016154047 A3 WO2016154047 A3 WO 2016154047A3 US 2016023247 W US2016023247 W US 2016023247W WO 2016154047 A3 WO2016154047 A3 WO 2016154047A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibodies
- binding proteins
- antigen binding
- fragments
- immunoconjugates
- Prior art date
Links
- 102000025171 antigen binding proteins Human genes 0.000 title abstract 3
- 108091000831 antigen binding proteins Proteins 0.000 title abstract 3
- 108700020796 Oncogene Proteins 0.000 title 1
- 102000043276 Oncogene Human genes 0.000 title 1
- 230000003834 intracellular effect Effects 0.000 title 1
- 229940127121 immunoconjugate Drugs 0.000 abstract 2
- 101710112752 Cytotoxin Proteins 0.000 abstract 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 abstract 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 abstract 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 abstract 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 abstract 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 abstract 1
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 1
- 239000002619 cytotoxin Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 239000012642 immune effector Substances 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Antigen binding proteins specific for an HLA-A2 restricted Ras peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, Fab fragments, F(ab')2 fragments, and single chain Fv fragments. Fusion proteins, such as scFv fusions with immunoglobulin or T-cell receptor domains, and bispecific antibodies incorporating the specificity of the antigen binding region for each peptide are also contemplated by the disclosure. Furthermore, immunoconjugates may include antibodies to which is linked a radioisotope, fluorescent or other detectable marker, cytotoxin, or other molecule are also encompassed by the disclosure. Among other things, immunoconjugates can be used for delivery of an agent to elicit a therapeutic effect or to facilitate an immune effector function.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/710,384 US11242405B2 (en) | 2015-03-20 | 2017-09-20 | Monoclonal antigen-binding proteins to intracellular oncogene products |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562136117P | 2015-03-20 | 2015-03-20 | |
US62/136,117 | 2015-03-20 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/710,384 Continuation US11242405B2 (en) | 2015-03-20 | 2017-09-20 | Monoclonal antigen-binding proteins to intracellular oncogene products |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2016154047A2 WO2016154047A2 (en) | 2016-09-29 |
WO2016154047A3 true WO2016154047A3 (en) | 2016-11-17 |
Family
ID=56979012
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/023247 WO2016154047A2 (en) | 2015-03-20 | 2016-03-18 | Monoclonal antigen-binding proteins to intracellular oncogene products |
Country Status (3)
Country | Link |
---|---|
US (1) | US11242405B2 (en) |
TW (1) | TW201643195A (en) |
WO (1) | WO2016154047A2 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3059755A1 (en) | 2017-04-26 | 2018-11-01 | Eureka Therapeutics, Inc. | Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof |
CA3062591A1 (en) | 2017-05-08 | 2018-11-15 | Gritstone Oncology, Inc. | Alphavirus neoantigen vectors |
WO2018213467A1 (en) * | 2017-05-16 | 2018-11-22 | The Johns Hopkins University | Manabodies and methods of using |
US20210061876A1 (en) * | 2017-12-29 | 2021-03-04 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | T cell receptors for tumor specific proteasome splice variants and uses thereof |
US20210261645A1 (en) * | 2018-05-23 | 2021-08-26 | Manysmart Therapeutics, Inc. | Bispecific t cell engager and uses thereof |
JP2022521513A (en) * | 2019-02-20 | 2022-04-08 | フレッド ハッチンソン キャンサー リサーチ センター | RAS neoantigen-specific binding proteins and their use |
WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
KR20220016137A (en) | 2019-05-30 | 2022-02-08 | 그릿스톤 바이오, 인코포레이티드 | modified adenovirus |
JP2023502625A (en) * | 2019-11-15 | 2023-01-25 | グリットストーン バイオ インコーポレイテッド | Antigen-binding proteins that target shared neoantigens |
CN115427057A (en) * | 2020-02-19 | 2022-12-02 | 艾琳治疗公司 | Molecules targeting mutant RAS proteins |
IL295624A (en) * | 2020-02-19 | 2022-10-01 | Aelin Therapeutics | Molecules targeting proteins |
JP2023541108A (en) | 2020-08-06 | 2023-09-28 | グリットストーン バイオ インコーポレイテッド | Multi-epitope vaccine cassette |
US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
JP2023551204A (en) * | 2020-11-20 | 2023-12-07 | シンク・セラピューティクス・インコーポレイテッド | Optimized peptide vaccine compositions and methods |
US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
CN116635064A (en) | 2020-12-18 | 2023-08-22 | 世纪治疗股份有限公司 | Chimeric antigen receptor systems with adaptive receptor specificity |
US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
CN114106136A (en) * | 2021-10-15 | 2022-03-01 | 北京臻知医学科技有限责任公司 | Tumor neogenesis antigen epitope peptide Pep2 and polymer and application thereof |
CN115505582B (en) * | 2022-05-17 | 2023-11-17 | 浙江大学 | Venom kynurenine aminotransferase PpVKAT of pteromalus puparum and application thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4898932A (en) * | 1985-01-29 | 1990-02-06 | E. I. Du Pont De Nemours And Company | Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins |
US5985587A (en) * | 1984-08-17 | 1999-11-16 | The Scripps Research Institute | Polypeptide-induced monoclonal receptors to protein ligands |
US7709002B1 (en) * | 1996-04-19 | 2010-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes |
US20140271644A1 (en) * | 2013-03-15 | 2014-09-18 | Memorial Sloan-Kettering Cancer Center | Combination/adjuvant therapy for wt-1-positive disease |
US20140294841A1 (en) * | 2011-04-01 | 2014-10-02 | Eureka Therapeutics, Inc. | T cell receptor-like antibodies specific for a wti peptide presented by hla-a2 |
US20150037334A1 (en) * | 2012-03-01 | 2015-02-05 | Amgen Research (Munich) Gmbh | Long life polypeptide binding molecules |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5443956A (en) * | 1985-01-29 | 1995-08-22 | Oncogene Science, Inc. | Detection, quantitation and classification of RAS proteins in body fluids and tissues |
US7361343B2 (en) * | 2003-01-21 | 2008-04-22 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
US7393531B2 (en) * | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
CN108137685B (en) * | 2015-03-23 | 2022-11-11 | 约翰·霍普金斯大学 | HLA-restricted epitopes encoded by somatic mutation genes |
-
2016
- 2016-03-18 WO PCT/US2016/023247 patent/WO2016154047A2/en active Application Filing
- 2016-03-21 TW TW105108660A patent/TW201643195A/en unknown
-
2017
- 2017-09-20 US US15/710,384 patent/US11242405B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5985587A (en) * | 1984-08-17 | 1999-11-16 | The Scripps Research Institute | Polypeptide-induced monoclonal receptors to protein ligands |
US4898932A (en) * | 1985-01-29 | 1990-02-06 | E. I. Du Pont De Nemours And Company | Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins |
US7709002B1 (en) * | 1996-04-19 | 2010-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes |
US20140294841A1 (en) * | 2011-04-01 | 2014-10-02 | Eureka Therapeutics, Inc. | T cell receptor-like antibodies specific for a wti peptide presented by hla-a2 |
US20150037334A1 (en) * | 2012-03-01 | 2015-02-05 | Amgen Research (Munich) Gmbh | Long life polypeptide binding molecules |
US20140271644A1 (en) * | 2013-03-15 | 2014-09-18 | Memorial Sloan-Kettering Cancer Center | Combination/adjuvant therapy for wt-1-positive disease |
Also Published As
Publication number | Publication date |
---|---|
US11242405B2 (en) | 2022-02-08 |
US20210332150A9 (en) | 2021-10-28 |
US20180134804A1 (en) | 2018-05-17 |
TW201643195A (en) | 2016-12-16 |
WO2016154047A2 (en) | 2016-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016154047A3 (en) | Monoclonal antigen-binding proteins to intracellular oncogene products | |
EA201401134A1 (en) | HLA-restructured peptidospecific antigen binding proteins | |
HRP20191462T1 (en) | Antibodies directed to her-3 and uses thereof | |
HRP20200390T1 (en) | Monoclonal antibodies against human b cell maturation antigen (bcma) | |
WO2018057735A8 (en) | Antibodies for siglec-15 and methods of use thereof | |
WO2016191246A3 (en) | T cell receptor-like antibodies specific for a prame peptide | |
HRP20231281T1 (en) | Bi specific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates | |
NZ750366A (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
PE20191208A1 (en) | ANTI-CD73 ANTIBODIES AND USES OF THEM | |
IN2012DN02535A (en) | ||
NZ709390A (en) | Folate receptor 1 antibodies and immunoconjugates and uses thereof | |
WO2003106495A3 (en) | Humanized monoclonal antiboby hpam4 | |
AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
ES2776179T3 (en) | Antibodies directed against surface determinants of S. aureus | |
EA201992526A1 (en) | STABILITIES OF ANTI-CTLA4 ANTIBODIES, SEPARATELY AND IN COMBINATION WITH ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1), AND METHODS OF APPLICATION | |
WO2013188864A4 (en) | Anti-cd22 anti-idiotypic antibodies and uses thereof | |
WO2017060322A3 (en) | Ptefb-inhibitor-adc | |
RU2016100892A (en) | ANTIBODIES AGAINST TWEAKR AND THEIR APPLICATION | |
MX2022011732A (en) | Anti-ccr7 antibody drug conjugates. | |
MX2020012567A (en) | Anti-ox40 antibodies and methods of use. | |
JP2019512207A5 (en) | ||
MX2022011951A (en) | Antibodies binding siglec15 and uses thereof. | |
PH12017500699A1 (en) | Antibodies that bind to ccr6 and their uses | |
MX2021011750A (en) | Anti-egfrviii antibodies and antigen-binding fragments thereof. | |
MX2020013606A (en) | Multi-specific antibody constructs. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16769443 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16769443 Country of ref document: EP Kind code of ref document: A2 |